SOPA image | Lightrocket | Getty image
Mortar On Tuesday, because the company temporarily suspended the key vaccine cargo to China, it issued the annual 2025 income guidelines for the year, which has not yet reached expectations.
Merck’s stocks fell more than 7 % in the listing and transactions on Tuesday.
The drug giant is expected to have a sales of $ 225 from US $ 64.1 billion to US $ 65.6 billion, which is lower than the analysts of LSEG surveys expected to US $ 67.31 billion. The company stated in a press release that the sales scope reflected a decision. From February and experienced at least mid -2025, Cada’s goods were stopped into China.
Gardasil is a vaccine to prevent HPV cancer Sales issue In a large number of shots in China, the country occupies most of the international income of the product.
A spokesman said in an email that the company believed that the suspension would allow “to reduce excess inventory faster” and help support its financial situation in Chinese partners. A spokesman said that Merck’s expected sales of Gadaris increased by 2 % to 4 %. At low -end, Galdisal did not have further freight, and at high -end, the country’s revenue was less than $ 1 billion.
When the company holds a recipient phone at 9 am in the United States at 9 am, investors will listen to more detailed information about Gardasil’s decision.
Sales sales may be very important for Merck to work hard from the best -selling cancer therapy KEYTRUDA, which may lose exclusion in 2028. Merck hopes that Gardasil’s support for Gardasil, 9 to 26 of China, will eventually help enhance the absorption lens.
A Merck spokesman said: “It is important to note that the dynamics of China’s Galdisa market can not reduce Merck’s confidence in its business in any way.”
Merck expects that the annual adjustment of revenue will be $ 8.88 to $ 9.03, which is usually consistent with the expectations of analysts. This prospect reflects the allegations of about 9 cents per share related to the license agreement of privately holding a pharmaceutical owner Lanova.
Sale KeytrudaOther oncology drugs and the company recently launched Cardiovascular Treatment helps Merck’s expectations of defeating the fourth quarter of 2024.
According to LSEG’s survey of analysts, Merck reported on the fourth quarter report in the fourth quarter:
- Earnings per share: $ 1.72 After adjustment and expected $ 1.62
- income: 15.62 billion US dollars and expected $ 15.49 billion
The company’s net income this quarter was $ 3.74 billion, $ 1.48 per share. In contrast, net loss is $ 1.23 billion, or 48 cents per share.
It does not include the cost of acquisition and reorganization. Merck received a $ 1.72 income per share in the fourth quarter. The adjustment and unsettled income reflect the cost of 23 cents per share related to Merck’s recent license agreement, including the development experiment agreement Obese medicine From Chinese pharmaceutical dealers.
Merck’s revenue this quarter was $ 15.62 billion, an increase of 7 % over the same period last year.
Pharmaceutical department
Merck’s pharmaceutical department has developed a wide range of drugs, revenue by $ 14.04 billion in the fourth quarter. This increased by 7 % over the same period a year ago.
Keytruda’s revenue in this quarter was US $ 7.84 billion, an increase of 19 % over the annual period. According to the estimation of Streetaccount, analysts expect sales to be US $ 7.63 billion.
This growth is due to the high absorption of the earlier cancer Keytruda and the strong demand for metastatic drugs. These cancers spread to other parts of the human body.
According to the estimate of Streetaccount, Gardasil’s sales were $ 1.55 billion, a 17 % decrease from the fourth quarter of 2023. Based on the estimate of Streetaccount, this is slightly lower than the analyst’s expected $ 1.58 billion.
Merck’s type 2 diabetes therapy Januvia’s sales in this quarter also fell to $ 487 million, a 38 % decrease of 38 % in the same period last year. The company said that the main reason for the decline is that the pricing of the United States is relatively low, China’s supply restrictions and the continuous competition of cheaper generic drugs in the international market.
According to Streetaccount data, this is $ 500 million in an analyst.
Januvia is one of the 10 drugs Medicare Drug Price NegotiationA policy of the “Reduction of Inflation” aims to make the expensive drugs of the elderly more affordable. The new negotiation price of the first round of drugs took effect in 2026.
Merck’s animal health department developed dogs, cats and cows’ vaccines and drugs, selling nearly $ 1.4 billion, an increase of 9 % over the same period last year. The company said that the price of products driven by the entire investment portfolio is higher.
